Clene Inc (CLNN)

Clene's stock has been influenced by insider trading, including sales by Chidozie Ugwumba and purchases by David Matlin. A registered direct offering secured over $28 million to support the CNM-Au8 program. Clene reported full-year 2025 financial results and highlighted an upcoming FDA meeting to discuss CNM-Au8 biomarker data, with plans to submit an NDA for ALS via an accelerated pathway in the first half of 2026. The company reported a quarterly loss but exceeded revenue expectations for fiscal year 2025. The stock has been volatile, with significant price fluctuations over the past year.

Demand for Clene Inc.'s investigational drugs is not typically subject to seasonal fluctuations. While the company also markets dietary supplements, their revenue impact is minimal, so any seasonality in their demand is unlikely to significantly affect the company's overall performance.

Clene, Inc. is a clinical-stage biopharmaceutical company focused on developing clean-surfaced nanotechnology therapeutics, particularly for neurodegenerative diseases like ALS, MS, and Parkinson's disease. Their lead drug candidate, CNM-Au8, is in clinical trials for these diseases, aiming to restore neuronal health. Other candidates include CNM-AgZn17, CNM-ZnAg, and CNM-PtAu7, targeting infectious diseases and cancer. In 2025, all of Clene's revenue came from dietary supplements (rMetx and KHC46).

Clene Inc. is headquartered in Salt Lake City, Utah, with R&D and manufacturing in Maryland. The company holds over 160 patents worldwide.

Clene Inc. has a "Moderate Buy" consensus rating from analysts, with a $33.00 average 12-month target price. Its reputation is tied to the progress of its clinical trials, particularly CNM-Au8. Positive developments, such as the FDA granting a Type C meeting, contribute positively. The company highlights its patented process and focus on diseases with few treatment options.

Clene's ownership is distributed among institutional owners (11.44% to 23.3%), including SymBiosis Capital Partners and Vanguard Group Inc; individual/insider owners (35.30% to 44.90%), with Jonathon Gay owning the most shares; and retail investors (approximately 40.02%).